Display options
Cite
Vidyashankar S, Babu UV, Patki PS. . Toxicol Rep. 2014;1:834-842doi: 10.1016/j.toxrep.2014.08.015.
Vidyashankar, S., Babu, U. V., & Patki, P. S. (2014). . Toxicology reports, 1834-842. https://doi.org/10.1016/j.toxrep.2014.08.015
Vidyashankar, Satyakumar, et al. "." Toxicology reports vol. 1 (2014): 834-842. doi: https://doi.org/10.1016/j.toxrep.2014.08.015
Vidyashankar S, Babu UV, Patki PS. . Toxicol Rep. 2014 Sep 04;1:834-842. doi: 10.1016/j.toxrep.2014.08.015. eCollection 2014. PMID: 28962295; PMCID: PMC5598397.
Copy Download .nbib Format: NLM
Share it on

Toxicol Rep. 2014 Sep 04;1:834-842. doi: 10.1016/j.toxrep.2014.08.015. eCollection 2014.

[No title available]

Toxicology reports

Satyakumar Vidyashankar, Uddagiri Venkanna Babu, Pralhad Sadashiv Patki

Affiliations

  1. Cell Biology, Research and Development, The Himalaya Drug Company, Makali, Bangalore 562162, India.
  2. Phytochemistry, Research and Development, The Himalaya Drug Company, Makali, Bangalore 562162, India.
  3. Medical Services Clinical Trials, Research and Development, The Himalaya Drug Company, Makali, Bangalore 562162, India.

PMID: 28962295 PMCID: PMC5598397 DOI: 10.1016/j.toxrep.2014.08.015

Abstract

The accumulation of advanced glycation end products (AGE) plays significant role in developing tubular hypertrophy during diabetic nephropathy (DN). Reactive oxygen species and nitric oxide (NO) are directly involved in the progression of DN. We have studied the effect of standardized

Keywords: AGE, advanced glycation end products; Advanced glycation end products (AGE); Antioxidant enzymes; CAT, catalase; Cyclic GMP; DN, diabetic nephropathy; GE, Gymnemasylvestre organic extract; GPx, glutathione peroxidase; GSH, reduced glutathione; Glutathione; Gymnemasylvestre; LPO, lipid peroxidation; MDA, malondialdehyde; NO, nitric oxide; Nitric oxide; SOD, superoxide dismutase; cGMP, cyclic guanosine monophosphate

References

  1. J Investig Med. 2002 Nov;50(6):443-51 - PubMed
  2. Semin Nephrol. 2007 Mar;27(2):130-43 - PubMed
  3. Toxicol In Vitro. 2002 Aug;16(4):339-47 - PubMed
  4. Endocr Rev. 2004 Dec;25(6):971-1010 - PubMed
  5. Exp Clin Endocrinol Diabetes. 2007 Feb;115(2):69-84 - PubMed
  6. J Ethnopharmacol. 1990 Oct;30(3):281-94 - PubMed
  7. Am J Physiol Endocrinol Metab. 2003 Oct;285(4):E744-53 - PubMed
  8. Am J Physiol Renal Physiol. 2005 Oct;289(4):F645-59 - PubMed
  9. Toxicol Appl Pharmacol. 2008 Dec 1;233(2):220-6 - PubMed
  10. Toxicol Pathol. 1996 Jan-Feb;24(1):77-83 - PubMed
  11. Hypertension. 2006 Oct;48(4):519-26 - PubMed
  12. Ann N Y Acad Sci. 2005 Jun;1043:784-92 - PubMed
  13. Nephrology (Carlton). 2005 Oct;10 Suppl:S7-10 - PubMed
  14. J Ethnopharmacol. 1990 Oct;30(3):295-300 - PubMed
  15. Methods Enzymol. 1984;105:121-6 - PubMed
  16. Endocr Metab Immune Disord Drug Targets. 2007 Jun;7(2):83-92 - PubMed
  17. Methods Enzymol. 1984;105:93-104 - PubMed
  18. J Pharmacol Exp Ther. 2007 Feb;320(2):591-8 - PubMed
  19. Toxicol Sci. 2009 Sep;111(1):109-19 - PubMed
  20. Kidney Int Suppl. 2001 Feb;78:S37-41 - PubMed
  21. Nature. 2001 Dec 13;414(6865):782-7 - PubMed
  22. J Immunol Methods. 1983 Dec 16;65(1-2):55-63 - PubMed
  23. J Pharm Sci. 1963 Jul;52:637-9 - PubMed
  24. Cell Biochem Biophys. 2005;43(2):289-330 - PubMed
  25. Curr Mol Med. 2006 May;6(3):351-8 - PubMed
  26. Anal Biochem. 1979 Jun;95(2):351-8 - PubMed
  27. J Am Soc Nephrol. 2006 Sep;17(9):2484-94 - PubMed
  28. Curr Vasc Pharmacol. 2004 Oct;2(4):335-41 - PubMed
  29. Curr Med Chem. 2007;14(5):585-99 - PubMed
  30. J Cardiometab Syndr. 2007 Spring;2(2):124-30 - PubMed
  31. Methods Enzymol. 1984;105:114-21 - PubMed
  32. Cardiovasc Res. 2005 Mar 1;65(4):823-31 - PubMed
  33. Methods Enzymol. 1985;113:548-55 - PubMed
  34. Am J Physiol Renal Physiol. 2001 Jul;281(1):F179-88 - PubMed

Publication Types